Related Experiment Video

Updated: Sep 27, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation

Xinting Zheng1, Jiamin Luo2, Wei Liu1

  • 1Cancer Center, The First Affiliated Hospital to Guangzhou University of Chinese Medicine, Guangzhou, China.

Drugs of Today (Barcelona, Spain : 1998)
|April 12, 2022
PubMed

Insights

Sotorasib is a targeted therapy for non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, showing significant efficacy and tolerable toxicity. Further research is needed to address resistance mechanisms and combination treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) frequently harbors KRAS mutations, historically posing treatment challenges.
  • The KRAS G12C mutation is a specific targetable alteration found in a subset of NSCLC patients.
  • Sotorasib represents a new class of drugs directly inhibiting KRAS G12C.

Purpose of the Study:

  • To review the mechanism of action of KRAS G12C inhibitors, focusing on sotorasib.
  • To summarize the clinical efficacy and safety data of sotorasib in NSCLC.
  • To explore resistance mechanisms and potential combination therapies for KRAS G12C-mutated NSCLC.

Main Methods:

  • Review of preclinical data and clinical trial results (Code-BreaK100).
  • Analysis of published literature on sotorasib and KRAS G12C inhibitors.
  • Discussion of emerging resistance pathways and investigational combination strategies.

Main Results:

  • Sotorasib demonstrated significant efficacy as a second-line treatment in patients with KRAS G12C-mutated NSCLC.
  • The drug exhibited a tolerable toxicity profile in the studied patient population.
  • Clinical data supports sotorasib monotherapy as a novel targeted approach for this specific NSCLC subtype.

Conclusions:

  • Sotorasib monotherapy offers a promising targeted treatment option for NSCLC patients with the KRAS G12C mutation.
  • Understanding and overcoming resistance mechanisms is crucial for long-term treatment success.
  • Further clinical investigation into combination therapies is warranted to enhance treatment outcomes.
Keywords:
KRAS G12C mutation inhibitorsNon-small cell lung cancer (NSCLC)Solid tumor therapySotorasibTargeted cancer therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
270
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K